Jamey Skillings

Learn More
The NCI Canada Clinical Trials Group conducted a phase II study of menogaril given intravenously every 4 weeks in low-grade non-Hodgkin's lymphoma. Fifteen of 26 eligible patients had had no prior therapy. Partial responses were seen in 9 patients (35%). Toxicity was moderate including myelosuppression, nausea, phlebitis, alopecia, and lethargy. This drug(More)
Our understanding of the biology of cancer and the application of this knowledge to cancer treatment has greatly outpaced what we know of the biology underlying the symptoms and toxic effects that therapies produce. These adverse effects of therapy cause substantial discomfort and distress to patients and their families, limit treatment tolerability and can(More)
The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of spirogermanium given daily for 5 days every 3 weeks to patients with poor prognosis non-Hodgkin's lymphomas. All patients had had a maximum of one prior treatment regimen. No responses were seen in 13 evaluable patients. Toxicity was primarily neurologic and mild or(More)
This paper examines the clinical effects of racism on its targets and, in particular, on its agents, the individuals who, wittingly or not, partake of the culture of racial privilege. It proposes a paradigm shift in regard to the clinical study of racism, and presents a structural model of racism, analogous to addiction as a disease, which holds that racism(More)
Hyperlipidemia is a common disease that leads to considerable morbidity and mortality. It is a major risk factor for the development of atherosclerosis. Hyperlipidemia is often undertreated by medical providers. Several large, randomized trials have established the benefit of aggressive management of hyperlipidemia. Effective treatment requires a(More)
DuP 937 (Teloxantrone) is a new anthrapyrazole intercalator that inhibits DNA synthesis. Experimental antitumor activity was demonstrated in several murine tumors and human tumor xenografts [1,2]. In a phase I study using a q 3 weeks i.v. bolus, neutropenia was the dose limiting toxicity. Occasional thrombocytopenia was noted. Nonhematologic toxicity(More)